Methods for treating obesity

Details Methods for treating obesity Methods for treating obesity

2011-03-22

2011-03-22

Devi, S. (Department: 1645)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S909000, C424S198100, C530S300000

Reexamination Certificate

active

07910548

ABSTRACT:
Methods for treating obesity are disclosed which comprise administration of a therapeutically effective amount of an amylin or an amylin agonist alone or in conjunction with another obesity relief agent.

REFERENCES:
patent: 4443619 (1984-04-01), Guthrie et al.
patent: 4960759 (1990-10-01), De Luca et al.
patent: 5124314 (1992-06-01), Cooper
patent: 5134164 (1992-07-01), Meglasson
patent: 5175145 (1992-12-01), Cooper
patent: 5187154 (1993-02-01), Phillips et al.
patent: 5234906 (1993-08-01), Young et al.
patent: 5264372 (1993-11-01), Beaumont et al.
patent: 5266561 (1993-11-01), Cooper et al.
patent: 5280014 (1994-01-01), Cooper et al.
patent: 5321008 (1994-06-01), Beaumont et al.
patent: 5364841 (1994-11-01), Cooper et al.
patent: 5367052 (1994-11-01), Cooper et al.
patent: 5376638 (1994-12-01), Young et al.
patent: 5462742 (1995-10-01), Bogentoft et al.
patent: 5498424 (1996-03-01), Klein et al.
patent: 5527788 (1996-06-01), Svec et al.
patent: 5578579 (1996-11-01), Lartey et al.
patent: 5656590 (1997-08-01), Rink et al.
patent: 5686411 (1997-11-01), Gaeta et al.
patent: 5690691 (1997-11-01), Chen et al.
patent: 5739106 (1998-04-01), Rink et al.
patent: 5739129 (1998-04-01), Aquino et al.
patent: 5830434 (1998-11-01), Taylor et al.
patent: 5877283 (1999-03-01), Shuldiner et al.
patent: 5900435 (1999-05-01), Meglasson
patent: 5932779 (1999-08-01), Lee et al.
patent: 5955443 (1999-09-01), Bennette et al.
patent: 5972621 (1999-10-01), Tartaglia et al.
patent: 6008242 (1999-12-01), Korsgaard et al.
patent: 6020361 (2000-02-01), Venkatesan
patent: 6043346 (2000-03-01), Kleyn et al.
patent: 6100047 (2000-08-01), Wilkison et al.
patent: 6110707 (2000-08-01), Newgard et al.
patent: 6114304 (2000-09-01), Kolterman et al.
patent: 6187991 (2001-02-01), Soeller et al.
patent: 6956026 (2005-10-01), Beeley et al.
patent: 2005/0197287 (2005-09-01), Mack et al.
patent: 0408294 (1990-07-01), None
patent: WO 91/16917 (1991-11-01), None
patent: WO 92/15317 (1992-09-01), None
patent: 9220367 (1992-11-01), None
patent: WO/9310146 (1993-05-01), None
patent: WO 94/26292 (1994-11-01), None
patent: WO 95/07098 (1995-03-01), None
patent: WO 95/28419 (1995-10-01), None
patent: WO 96/37612 (1996-11-01), None
patent: WO 96/40220 (1996-12-01), None
patent: WO/9640196 (1996-12-01), None
Kolterman et al. (I) Diabetologia 39: 492-496, Apr. 1996.
Moyses et al. Diabetic Med. 13 (suppl. 1): 34-38, Sep. 1996.
Thompson et al. Diabetes 46: 632-636, Apr. 1997.
Cooper et al. Biochim. Biophys. Acta 1014(3): 247-258, Abstract, 1989.
Weisser et al. J. Clin. Pharmacol. 37(6): 453-473, Jun. 1997.
Morley et al. Am. J. Physiol. 267: R178-R184, 1994.
Morley et al. Can. J. Physiol. Pharmacol. 73: 104-1046, 1995.
Lutz et al. (Physiol. & Behavior 55(5): 891-895, abstract, 1994.
Kolterman, Diabetic Med. 14 (suppl. 1): s35-s38, Jun. 1997.
Exp. Opin. Ther. Patents 4(11): 1383-1384, 1994.
Koopman et al. Neth. J. Med. 41 (1-2): 82-90, 1992.
Ludwik, Wien Klin. Wochenster 109 (11): 379-383, Jun. 6, 1997, abstract.
Rowland et al. CNS Drugs, Jun. 1997, 7(6): 419-426.
Porte, Diabetes, 40( ): 166-180, 1991.
Young et al. Drug Dev. Res. 37: 231-48, 1996.
Janes et al. Diabetes, 45 (suppl. 2): A 865, p. 235A, 1996.
Colburn et al. J. Clin. Pharmacol. 36: 13-24, 1996.
Thompson et al. Abstract Book, 55th Annual Meeting and Scientific Sessions, Jun. 10-13, 1995, Georgia World Congress Center, Atlanta, Georgia. Diabetes 44: suppl. 1, Ab. 469, p. 127A, 1995.
Morley et al. Peptides 12: 865-869, 1991.
Lutz et al. Br. Vet. J. 149 (6): 527-536, Nov.-Dec. 1993, abstract.
Thomas et al. Circulation 91: 764-770, abstract, 1995.
Johnston et al. J. Hypertension 10: 393-397, abstract, 1992.
Scheen et al. Drugs 54: 355-368, Sep. 1997, abstract.
Stogdale et al. Cornell Vet. 76: 156-174, abstract, 1986.
Griver et al. Nutrition Res. 14: 465-483, abstract, 1994.
Arnelo et al. Am. J. Physiol. 271: 6 Pt 2: R1654-R1659, Dec. 1996.
Arnelo et al. Scand. J. Gastroenterol. 31: 83-89 Jan. 1996.
Wang et al. Diabetes 42 (2): 330-335, 1993, abstract.
Weintraub et al. Nutrition Rev. 49: 237-249, 1989.
Thompson et al. Diabetes 48: Suppl. 1, p. 30A, 0116, May 2, 1997.
The Random House Dictionary, (Ed) Flexner et al., Random House, p. 32, New York, 1984.
Frishman et al. In: Cardiovascular Pharmacotherapeutics. (Eds) Frishman WH et al. McGraw-Hill Health Professions Division, New York, Chapter 48, pp. 1093-1114, Feb. 1997.
Kong et al. Diabetologia 40: 82-88, Jan. 1997.
Jonderko et al. Aliment. Pharmacol. Ther. 5: 413-418, 1991.
Morley et al. Pharmcol. Biochem. Behav. 44: 577-580, 1993.
Jonderko et al. Israel J. Med. Sci. 25: 20-24, 1989.
Frank et al. Gastroenterology 109: 755-785, 1995.
Balasubramaniam et al. Peptides 12: 919-924, 1991.
Kong et al. Diabetes 46: Suppl. 1, 154A, 1997.
Clementi et al. Experientia 52: 677-679, 1996.
Brown et al. Diabetes 43: Suppl. 1: 172A, 1994.
Wright et al. Gastroenterology 84: 747-751, 1986.
Edwards et al. Life Sci. 51: 1819-1912, 1992.
Kolterman et al. Diabetologia 37: Suppl. 1: A72, 278, 1994.
Young et al. Diabetes 45: Suppl. 2, p. 187A, A689, 1996.
Tsanev. Vutr. Boles 23: 12-17, 1984, abstract.
Szabo et al. Vnitr Lek. 44: 145-150, Mar. 1998.
Kosmiski et al. Curr. Opin. Endocrin. Diabet. 4: 36-39, 1997.
Baron et al. Current Drug Targets—Immune, Endocrine & Metabolic Disorders 2: 63-82, 2002.
Ratner et al. Diabetes Technol. Ther. 4: 51-61, 2002.
Hollander et al. Obesity Res. 12: 661-668, Apr. 2004.
Kopelman Editotial. Internat. J. Obesity 23: Suppl. 7, S1, 1999.
Itasaka et al. Psychiatr. Clin. Neurosci. 54: 340-341, Jun. 2000, abstract.
Pi-Sunyer. Diabetes Care 28: 1526-1527, 2005.
Olefsky JM. In: Harrison's Principles of Internal Medicine, 12th Edition, McGraw-Hill Book Company, pp. 411-416, 1961.
Kolterman et al., “Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue,”Diabetes Care18(8):(Abstract) (1995).
Kong et al., “Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM,”Diabetologia40(1):82-88 (1997).
Kong et al., “The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM,”Diabetologia41(5):577-583 (1998).
Nyholm et al., “Acute effects of the human amylin analog AC137 on basal and insulin-stimulated eugycemic and hypoglycemic fuel matabolism in patients with insulin-dependent diabetes mellitus,”J. Clin. Endocrinol. Metab. 81(3):1083-1089 (1996).
Schmitz et al., “Effects of amylin and the amylin agonist pramlintide on glucose metabolism,”Diabetic Med. 14(2):S19-S23 (1997).
Thompson et al., “Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations,”Diabetologia40(11):1278-1285 (1997).
Thompson et al., “Pramlintide: A human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes,” Diabetic Med. 14(7):547-555 (1997).
Alam et al., “Selective Antagonism of Calcitonin-Induced Osteoclastic Quiescence (Q Effect) by Human Calcitonin Gene-Related Peptide-(Val8Phe37), ”Biochem. Biophys. Res. Commun., 179(1):134-139 (1991).
Beaumont et al., “Regulation of Muscle Glycogen Metabolism by CGRP and Amylin: CGRP Receptors Not Involved,”Br. J. Pharmacol., 115(5):713-715 (1995).
Brain et al., “Amylin Amide, Which Is Structurally Similar to Calcitonin Gene-Related Peptide (CGRP), Stimulates Increased Blood Flow In Vivo,”Eur. J. Pharmacol., 183:2221 (1990).
Bray, G.A., “Drug Treatment of Obesity,”Am. J. Clin. Nutr., 55:538S-544S (1992).
Bray, G.A. “Treatment for Obesity: A Nutrient Balance/Nutrient Partition Approach,”Nutrition Reviews, 49:33-45 (1991).
Broderick et al., “Human and Rat Amylin Have No Effects on Insulin Secretion in Isolated Rat Pancreatic Islets,”Biochem. Biophys. Res. Commun., 177(3):932-938 (1991).
Chance et al.

Affiliated with

Also associated with

Rating

Methods for treating obesity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for treating obesity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating obesity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2774883